StreetInsider.com News Articles

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Wed, 17 Jun 2026 07:30:00 -0400

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.

BIO International Convention
June 22-25, 2026, San Diego, California
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

Leerink Partners Therapeutics Forum 2026
July 14-15, 2026, Boston, Massachusetts
Trevi Representatives: David Hastings, CFO, and Farrell Simon, Pharm.D., CCO

ERS Cough

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Mathers Edward T

Thu, 04 Jun 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260604/26606124.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Mathers Edward T

Thu, 04 Jun 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260604/26606124.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: VANLENT ANNE

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605561.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: VANLENT ANNE

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605561.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Heffernan Michael Thomas

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605566.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Heffernan Michael Thomas

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605566.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Meeker David P

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605567.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Meeker David P

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605567.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Colangelo Dominick

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605574.html

Form 4 Trevi Therapeutics, Inc. For: Jun 03 Filed by: Colangelo Dominick

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605574.html

Form 8-K Trevi Therapeutics, Inc. For: Jun 03

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605580.html

Form 8-K Trevi Therapeutics, Inc. For: Jun 03

Thu, 04 Jun 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260604/26605580.html

Trevi Therapeutics (TRVI) PT Raised to $30 at Stifel

Fri, 08 May 2026 08:43:41 -0400
Stifel analyst Annabel Samimy raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $30.00 (from $18.00) while maintaining a Buy rating.

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400
si-local-file:///var/storage/secattach/20260507/26455660.html

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400
si-local-file:///var/storage/secattach/20260507/26455660.html

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400
si-local-file:///var/storage/secattach/20260506/26441784.html

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400
si-local-file:///var/storage/secattach/20260506/26441784.html

Trevi Therapeutics (TRVI) PT Raised to $21 at B.Riley

Wed, 06 May 2026 09:21:09 -0400
B.Riley analyst Mayank Mamtani raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $21.00 (from $16.00) while maintaining a Buy rating.

Trevi Therapeutics (TRVI) PT Raised to $20 at Morgan Stanley

Wed, 06 May 2026 08:15:59 -0400
Morgan Stanley analyst Judah Frommer raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $20.00 (from $18.00) while maintaining a Overweight rating.

Trevi Therapeutics (TRVI) PT Lowered to $23 at Needham

Wed, 06 May 2026 07:21:44 -0400
Needham analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $23.00 (from $24.00) while maintaining a Buy rating.

Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Wed, 06 May 2026 00:49:17 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $18.00 price target on Trevi Therapeutics (NASDAQ: TRVI)
The analyst comments: “We reiterate our Buy rating on TRVI, $18 TP. Following a productive EOP2 meeting with FDA, TRVI will initiate its pivotal program for Haduvio in IPF-CC this quarter, based on a prudent two trial design with primary endpoint readouts at 12 and 24 weeks (first data expected 2027). We think the two-trial pivotal design was prudent in light of still-untested one-trial approach proposed by FDA. TRVI’s next regulatory meeting will serve to solidify clinical and regulatory plans to expand into non-IPF